3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Other solid neoplasm
2
NET
2
Endocrine
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neuroendocrine Tumors
28
Neoplasms
4
Melanoma
4
Carcinoma, Neuroendocrine
4
Sarcoma
3
Pheochromocytoma
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Gastro-enteropancreatic neuroendocrine tumor
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Carcinoid Tumor
3
Breast Neoplasms
3
Thyroid Neoplasms
2
Thymus Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Paraganglioma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Meningioma
2
Lung Neoplasms
2
Insulinoma
2
Head and Neck Neoplasms
2
Interventions
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thymus Neoplasms
×
NET
×
30 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT02012699
2026-05-05
iCaRe2
University of Nebraska
Recruiting
999,999 enrolled